Abilify Therapy for Reducing Comorbid Substance Abuse
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or
drug dependence with comorbid psychiatric conditions will lead to:
- Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow
Back (TLFB) and the Addiction Severity Index (ASI)
- Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving
Scale
- Reduction in symptoms of co-morbid psychiatric disorders compared to before starting
aripiprazole.